Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics

FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar